SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-19-129496
Filing Date
2019-04-30
Accepted
2019-04-30 16:35:02
Documents
6
Effectiveness Date
2019-04-30

Document Format Files

Seq Description Document Type Size
1 DEFA14A d737168ddefa14a.htm DEFA14A 45930
2 GRAPHIC g737168stamp2.jpg GRAPHIC 1234
3 GRAPHIC g737168stamp3_a.jpg GRAPHIC 2870
4 GRAPHIC g737168stamp3_b.jpg GRAPHIC 1248
5 GRAPHIC g737168stamp4.jpg GRAPHIC 1245
6 GRAPHIC g737168stamp5.jpg GRAPHIC 1239
  Complete submission text file 0001193125-19-129496.txt   58475
Mailing Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080 650-278-8930
Atara Biotherapeutics, Inc. (Filer) CIK: 0001604464 (see all company filings)

IRS No.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36548 | Film No.: 19782350
SIC: 2836 Biological Products, (No Diagnostic Substances)